Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD

Jie Lin; Jie Lin; Binbin Xue; Dewei Xie; Jia Li; Juyuan Pan; 朱兰兵; Qiaowen Tong; Jing Lin; Jing Lin; Ruofan Zhu; Xi Zhang; Junhui Xia; Xiang Li

doi:10.1002/acn3.70412

April 24, 2026Annals of Clinical and Translational NeurologyOpen Access

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to compare the effectiveness and safety of inebilizumab versus rituximab in treating AQP4-IgG positive NMOSD.
Real-world cohort study design
Comparison of relapse rates between inebilizumab (INE) and rituximab (RTX)
Assessment of safety profile, including incidence of hypogammaglobulinemia
INE showed a trend toward lower relapse risk compared to RTX
INE demonstrated a manageable safety profile
Increased incidence of hypogammaglobulinemia with INE

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Real-world cohort study shows INE may reduce relapse risk in AQP4-IgG positive NMOSD, suggesting a favorable safety profile.

Abstract

In this real-world cohort, INE showed a trend toward lower relapse risk compared to RTX, whereas demonstrating a manageable safety profile with increased incidence of hypogammaglobulinemia.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/69edac074a46254e215b3d5a https://doi.org/10.1002/acn3.70412

View Full Paper

Ask AI

Bookmark

Share

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4 ‐ IgG ‐Positive NMOSD

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading